Q-omics provides the consensus-scored SHQ1 profile across patient tissues and cancer cell-line models. SHQ1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SHQ1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, SHQ1 RNA expression shows 20,494 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, THCA, and ACC as cancer lineages where SHQ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHQ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHQ1 survival associations across molecular data types. SHQ1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHQ1 RNA expression–survival associations across cancer types. High SHQ1 expression shows unfavorable associations in LGG, CESC and LIHC, but favorable associations in BRCA, READ and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify BRCA as the clearest survival context for SHQ1 RNA expression.
This table summarizes SHQ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SHQ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHQ1 shows lower tumor expression in THCA and higher tumor expression in LIHC, STAD, COAD, BLCA and BRCA. The THCA box plot shows higher SHQ1 RNA expression in normal versus tumor tissue (log2 FC = −0.772, t-test p < 0.001).
This table shows molecular features associated with SHQ1 in patient tissues and cancer cell lines. In patient samples, SHQ1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SHQ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
